As the voice of Arizona’s Biotech and Medtech industry, AZBio shares information about our community and our innovators locally, nationally, and globally. Continue reading
Venture Madness 2021, presented by Invest Southwest in partnership with the Arizona Commerce Authority, is now accepting applications through June 3.
The annual event is Arizona’s longest running Capital Conference and early-stage pitch competition, highlighting some of the most promising startups in the state. This year, the live competition will offer both in-person and virtual options and feature applicants chosen by an expert panel of judges.
On October 6-7, finalists will compete head-to-head in several industry categories and gain exclusive access to the region’s most active accredited investors.
Help spread the word among your networks and encourage any innovative, tech-based startups you know to apply!
With the acquisition, Castle expects to make available the most comprehensive molecular testing offering for difficult-to-diagnose melanocytic lesions.Continue reading
Merck will also donate more than $5 million in supplies and equipment to aid relief efforts in IndiaContinue reading
– Gilead Will Donate a Minimum of 450,000 Vials of Veklury® to the Government of India –
– Company Will Continue to Support Expansion of Local Production Capacity –
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to new research.
A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which could help doctors and patients to decide on the best treatment options.Continue reading
- About 90,000 women globally die from endometrial cancer each year1
- VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)
- Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy
Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystrophy
TUCSON, Ariz., April 22, 2021 — Critical Path Institute (C-Path) announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics Platform (RDCA-DAP®). The D-RSC database includes data from Duchenne muscular dystrophy (DMD) clinical trials, natural history studies and clinical data collections. The contributors of these datasets have given permission for this data to be shared externally to accelerate therapy development for DMD.